Canada Markets closed

Brooklyn ImmunoTherapeutics, Inc. (BTX)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
6.73-0.83 (-10.98%)
At close: 4:00PM EST
Full screen
Trade prices are not sourced from all markets
Previous Close7.56
Open7.55
Bid6.63 x 1200
Ask6.70 x 1100
Day's Range6.65 - 7.66
52 Week Range3.59 - 80.67
Volume872,818
Avg. Volume634,038
Market Cap287.268M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
All
News
  • GlobeNewswire

    Brooklyn ImmunoTherapeutics Announces Filing of Registration Statement for Proposed Secondary Offering of Shares Issued in Previously Announced Novellus Acquisition

    NEW YORK, Nov. 19, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (Nasdaq: BTX) (“Brooklyn”) today announced that on November 18, 2021 it filed with the Securities and Exchange Commission a registration statement on Form S-1 relating to the proposed public offering by certain selling stockholders of up to 6,281,454 shares of Brooklyn’s common stock received in connection with Brooklyn’s acquisition of Novellus, Inc. in July 2021. Brooklyn will not receive any proceeds from any shares

  • GlobeNewswire

    Brooklyn ImmunoTherapeutics Announces Third Quarter 2021 Financial Results

    NEW YORK, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (Nasdaq:BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine, gene editing, and cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, today announced financial results for the quarter ended September 30, 2021. Financial and corporate highlights for the quarter ended September 30, 2021 and subsequently include the following: Transitioned fr

  • GlobeNewswire

    Brooklyn ImmunoTherapeutics to Move Stock Exchange Listing to Nasdaq

    Ticker Symbol to Remain “BTX”NEW YORK, Oct. 14, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, today announced it will transfer its common stock listing from the NYSE American to the Nasdaq Global Market, effective upon the market close on October 22, 2021. Brooklyn’